Regardless of constitutive activation of JAK/STAT signaling, due to somatic mutations in JAK2(V617F), calreticulin or the thrombopoietin receptor, it is hypothesized that other non-genetic factors, including inflammatory mediators, are involved in the pathogenesis of ET. The gene discussed is JAK2; the disease is essential thrombocythemia.